The research team, led by Chia-Ming Lin, Pei-Yun Li, Yu-Nan Huang, and Pen-Hua Su of Chung Shan Medical University Hospital in Taiwan, together with collaborators including Gideon Meyerowitz-Katz at the University of Wollongong in Australia, used the TriNetX US Collaborative Network, a massive repository of de-identified electronic health records spanning 2017 to 2025. Rather than running a prospective trial, which would take years and cost millions, they employed a technique known as target trial emulation. This approach borrows the design logic of a randomized controlled trial — defining eligibility criteria, treatment strategies, and follow-up windows as if a trial were being conducted — and then applies that blueprint to observational data, using statistical tools to approximate the balance that randomization would have achieved.

Specifically, the investigators emulated three separate active-comparator target trials in adults with type 2 diabetes undergoing thyroidectomy. Each trial compared preoperative continuation of a GLP-1 receptor agonist against a different alternative: dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, or usual care. To reduce the chance that sicker patients were systematically channeled into one drug class, the cohorts were 1:1 propensity score matched, a method that pairs patients across treatment groups based on their baseline characteristics. Cox proportional hazards models then estimated hazard ratios for each outcome, the standard statistical measure of how quickly events accumulate in one group relative to another over time.

The safety question at the heart of the study concerned aspiration, the feared complication in which stomach contents enter the airway during anesthesia. Because GLP-1 receptor agonists delay gastric emptying, anesthesiology societies have debated whether patients should hold these medications before surgery. In this analysis, however, aspiration-specific events fell below the minimum reportable cell size in every comparison and every postoperative window — meaning so few events occurred that reporting a hazard ratio would risk identifying individual patients. A broader postoperative respiratory composite outcome, which was prespecified precisely to capture this signal indirectly, showed no excess in the GLP-1 receptor agonist groups. For a surgical community hungry for reassurance, that absence of harm is itself a meaningful finding.

The thyroidectomy-specific complications told a similarly reassuring story. Recurrent laryngeal nerve injury, one of the most dreaded complications of thyroid surgery because it can permanently alter the voice, showed no excess in patients who continued GLP-1 receptor agonists. Hypocalcemia, a drop in blood calcium that follows disturbance of the parathyroid glands during thyroidectomy, was more frequent with GLP-1 receptor agonists than with SGLT2 inhibitors in the primary analysis, with a hazard ratio of 1.43 and a 95 percent confidence interval of 0.96 to 2.12 — a signal that grazed but did not cross the threshold of statistical significance. Notably, that signal did reach nominal significance in sensitivity analyses restricted to a two-year exposure window and to new users of the drugs, a pattern the authors treated with caution rather than as proof of a causal link.

The metabolic findings were more surprising. Patients who continued GLP-1 receptor agonists before surgery had a lower risk of diabetic ketoacidosis over 24 months compared with those on DPP-4 inhibitors, with a hazard ratio of 0.56 and a 95 percent confidence interval of 0.34 to 0.91. Diabetic ketoacidosis is a life-threatening emergency in which the body, starved of effective insulin action, produces dangerous levels of blood acids, and it has been a particular concern with SGLT2 inhibitors. The lower DKA risk was reproduced in both the exposure-window and new-user designs, lending it more internal consistency than many observational findings enjoy.

Mortality results generated the study’s most eye-catching numbers. GLP-1 receptor agonist continuation was associated with lower 24-month all-cause mortality compared with DPP-4 inhibitors, at a hazard ratio of 0.49 (95 percent confidence interval 0.26 to 0.92), and compared with SGLT2 inhibitors, at a hazard ratio of 0.39 (95 percent confidence interval 0.19 to 0.78). In plain terms, patients on GLP-1 drugs appeared roughly half as likely to die within two years as matched peers on the comparator drugs. Yet the authors themselves immediately tempered the excitement: the mortality findings were not reproduced in the exposure-window and new-user designs, mortality over the immediate postoperative periods of days 1 to 30 and 1 to 90 fell below the minimum reportable cell size in every comparison, and none of the significant results survived correction for multiple comparisons.

That last point deserves emphasis, because it captures the epistemological honesty that distinguishes careful pharmacoepidemiology from headline-chasing. When researchers test many outcomes across many comparisons, some associations will appear statistically significant by chance alone — the multiple-comparisons problem. Corrections such as false discovery rate control adjust for this inflation, and in this study every nominally significant finding dissolved under that scrutiny. The team also deployed negative-control outcomes, outcomes with no plausible biological connection to the drugs under study, and these were null, probing for residual confounding and finding no obvious trace of it. Still, the authors concluded that the lower DKA and mortality risks should be regarded as hypothesis-generating rather than as evidence for clinical action.

The practical takeaway for clinicians is nonetheless concrete. In adults with type 2 diabetes undergoing thyroidectomy, preoperative GLP-1 receptor agonist continuation was not associated with excess perioperative harm — no excess aspiration-related signal, no excess respiratory composite events, no excess recurrent laryngeal nerve injury. For surgeons and anesthesiologists who have faced the dilemma of whether to interrupt a patient’s diabetes therapy before an operation, the study offers the most procedure-specific evidence to date that continuation is compatible with perioperative safety. The findings align with a broader shift in perioperative medicine, where blanket drug-holding rules are increasingly replaced by procedure- and patient-specific risk assessments grounded in real-world data.

The study’s design also matters for how its results should be used. Because it emulated target trials in retrospectively collected, de-identified records, it was not a registered prospective clinical trial, and its matched cohorts — 722, 736, and 611 patients per arm across the three comparisons — were large but finite. Rare events like aspiration can escape detection even in cohorts of this size, and residual confounding can never be fully excluded in non-randomized data. The work was funded by Taiwan’s National Science and Technology Council and institutional grants from Chung Shan Medical University Hospital, with the funding sources having no role in the analysis or manuscript. The authors declare no competing interests. What the study delivers is a rigorously constructed, transparently reported foundation — one that flags no perioperative danger from continuing GLP-1 receptor agonists before thyroidectomy, and that sketches intriguing hypotheses about metabolic and survival benefits that only properly randomized trials can confirm.

Subject of Research: Perioperative safety of preoperative GLP-1 receptor agonist continuation in adults with type 2 diabetes undergoing thyroidectomy

Article Title: Preoperative GLP-1 receptor agonist continuation and perioperative safety after thyroidectomy in type 2 diabetes: a target trial emulation using a retrospective multicenter cohort

Article References: Lin, C.-M., Li, P.-Y., Chen, J.-C., Li, P.-H., Yang, H.-W., Meyerowitz-Katz, G., Huang, Y.-N., & Su, P.-H. (2026). Preoperative GLP-1 receptor agonist continuation and perioperative safety after thyroidectomy in type 2 diabetes: a target trial emulation using a retrospective multicenter cohort. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02537-y

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02537-y

Keywords: GLP-1 receptor agonist, thyroidectomy, type 2 diabetes, perioperative safety, aspiration, diabetic ketoacidosis, hypocalcemia, recurrent laryngeal nerve injury, target trial emulation, propensity score matching, pharmacoepidemiology, TriNetX

Vocal fold paralysis occurs when the nerves supplying the vocal folds, most commonly the recurrent laryngeal nerve, are damaged or dysfunctional, leaving one or both folds unable to move properly. The condition is far more often unilateral than bilateral, and the two presentations pose fundamentally different clinical problems. Patients with unilateral vocal fold paralysis typically struggle with a breathy, weak voice, difficulty swallowing, and an elevated risk of aspiration because the paralyzed fold cannot close the glottis during speech or swallowing. Bilateral paralysis, by contrast, can be life-threatening: when both folds are immobile near the midline, the airway itself may be obstructed, sometimes constituting a surgical emergency. Most cases in adults follow iatrogenic injury during thyroid, cardiothoracic, or esophageal surgery, while malignancies of the lung and larynx, stroke, trauma, and idiopathic causes account for much of the remainder.

The therapeutic arsenal for these patients is broad and reflects the divergent goals of treatment. For unilateral paralysis, surgeons aim to reposition or bulk up the immobile fold so that it can meet its functioning partner. Temporary options include hyaluronic acid injection, while calcium hydroxylapatite provides medialization lasting roughly eighteen months on average and autologous fat around six to twelve months. When the glottal gap exceeds three millimeters, framework surgery such as type I thyroplasty, sometimes combined with arytenoid adduction, is generally preferred and achieves voice improvement in eighty to ninety percent of cases. Laryngeal reinnervation, which reroutes nerve supply such as the ansa cervicalis to the recurrent laryngeal nerve, does not restore dynamic movement but improves static competence, muscle tone, and long-term stability by preventing denervation atrophy. For bilateral paralysis, the priority shifts to enlarging the airway through posterior cordotomy, partial or subtotal arytenoidectomy, or cordectomy, procedures that achieve decannulation rates of eighty-seven to one hundred percent among tracheostomized patients, albeit with substantial revision needs.

Despite the maturity of these techniques, the evidence base for their safety has remained surprisingly thin. Most published series are small, single-center studies drawn from homogeneous patient populations, leaving clinicians without reliable, generalizable estimates of perioperative risk. The new analysis was designed to close that gap. The investigators queried the ACS-NSQIP database, a prospectively maintained registry that collects standardized perioperative data from more than six hundred participating hospitals, using diagnostic codes for vocal fold paralysis and paresis together with a comprehensive list of procedural codes covering injection laryngoplasty, framework surgery, glottis-enlarging procedures, and reinnervation. Complications were aggregated into composite outcomes: surgical complications such as infections, wound dehiscence, and bleeding; medical complications ranging from pneumonia and reintubation to stroke, cardiac arrest, and sepsis; and an overall composite that also included reoperation.

The resulting cohort closely mirrored the expected epidemiology of the disease. Of the 931 patients, 857, or ninety-two percent, had unilateral paralysis, while seventy-four, or eight percent, had bilateral disease. Mean age was about sixty years in both groups, body mass index averaged twenty-nine kilograms per square meter, and roughly fifty-five percent of patients were women, a balanced sex distribution the authors suggest may more accurately reflect the true epidemiology than the divergent ratios reported in smaller studies. The majority of patients in both groups were classified as American Society of Anesthesiologists class three, indicating severe systemic disease, underscoring that these procedures are routinely performed in medically complex individuals. Most operations, around ninety percent in each group, were completed on an outpatient basis, with mean operative times of roughly one hundred minutes.

The safety outcomes were remarkably consistent across the two diagnostic groups. The overall complication rate was 3.4 percent for unilateral cases and 2.7 percent for bilateral cases, a difference that was not statistically significant. Reoperation was required in 0.93 percent of unilateral and 1.4 percent of bilateral patients, while surgical complications occurred at nearly identical rates of about 1.5 percent in both groups. Medical complications arose in 1.4 percent of unilateral cases and none of the bilateral cases. There were no significant between-group differences in superficial or deep infections, organ space infection, wound dehiscence, bleeding, pneumonia, reintubation, prolonged ventilation, urinary tract infection, stroke, cardiac arrest, myocardial infarction, deep vein thrombosis, sepsis, or septic shock. Notably, the analysis recorded no cases of sepsis, septic shock, or organ-space infection at all, findings the authors interpret as validation of established perioperative safety protocols.

The single patient who required ventilation beyond forty-eight hours illustrates how baseline frailty, rather than the procedure itself, can drive adverse outcomes. The individual was an eighty-year-old, ASA class three patient with congestive heart failure and hypertension who experienced a cascade of postoperative events including unplanned reintubation, cardiopulmonary resuscitation, blood transfusion, reoperation, and prolonged ventilation. Although no causal inference can be drawn from a single observation, the case highlights the importance of preoperative risk stratification in this population. This concern is particularly relevant given the burden of chronic pulmonary disease in the cohort: 8.1 percent of patients had chronic obstructive pulmonary disease, yet only six cases of pneumonia, or 0.64 percent, and a single reintubation, or 0.11 percent, were observed across the entire study period, figures consistent with or better than historical single-center series.

These results arrive amid ongoing debate about the optimal timing of surgery. Because spontaneous recovery occurs in a meaningful fraction of patients, with reported remission rates for idiopathic unilateral paralysis ranging from thirty to sixty-nine percent and most evidence clustering near the lower end, guidelines generally recommend deferring definitive procedures such as injection glottoplasty or type I thyroplasty for at least six and ideally up to twelve months. Prolonged denervation, however, causes progressive atrophy of the intrinsic laryngeal muscles that can compromise eventual functional outcomes, and significant aspiration or threatened airway protection may justify earlier temporary augmentation. Currently, no diagnostic marker reliably distinguishes patients who will recover spontaneously from those who will need surgery, forcing clinicians to balance the window for neural recovery against the risk of irreversible muscular deterioration on a case-by-case basis.

The authors are careful to frame the study as a measure of safety rather than efficacy. The ACS-NSQIP database captures only thirty days of follow-up, so long-term outcomes such as sustained voice quality, swallowing function, and airway stability fall outside its scope. Nor does the registry provide granular detail on specific techniques, primary versus revision procedures, or the underlying etiology of paralysis, and the binary structure of its outcome variables may underrepresent subtler morbidities like persistent dysphonia or delayed aspiration recovery. Because the database largely reflects North American practice, the findings may not generalize fully to international settings. Nevertheless, by transcending the single-center biases that have limited prior work, the analysis establishes a dependable benchmark: thirty-day morbidity after vocal fold paralysis surgery is low, comparable between unilateral and bilateral disease, and low enough to reassure both surgeons and the patients they counsel.

Subject of Research: Thirty-day perioperative safety of surgical intervention for unilateral and bilateral vocal fold paralysis in a multicenter ACS-NSQIP cohort

Article Title: Thirty-day perioperative safety following surgical intervention for unilateral and bilateral vocal fold paralysis: a multicenter ACS-NSQIP analysis

Article References: Schaschinger, T., Hoch, C. C., Knoedler, L., Niederegger, T., Dyhr, W. J., Hundeshagen, G., Lellouch, A. G., Voss, L. J., & Voss, J. O. (2026). Thirty-day perioperative safety following surgical intervention for unilateral and bilateral vocal fold paralysis: a multicenter ACS-NSQIP analysis. BMC Plastic and Reconstructive Surgery, 2(1), Article 26. https://doi.org/10.1186/s44452-026-00039-3

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00039-3

Keywords: vocal fold paralysis, ACS-NSQIP, perioperative safety, phonosurgery, thyroplasty, injection laryngoplasty, laryngeal reinnervation, bilateral vocal fold paralysis, unilateral vocal fold paralysis, surgical complications, otolaryngology, medialization